Therapy to Watch: Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) PDUFA Date

Atara Biotherapeutics has announced that the FDA has accepted its Biologics License Application (BLA) resubmission for tabelecleucel (Tab-cel®), with a proposed indication as monotherapy for treatment of adult and pediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. The FDA granted Priority Review and set a Prescription Drug User Fee Act (PDUFA) date of March 31 2027.

https://investors.atarabio.com/news-events/press-releases/detail/390/atara-biotherapeutics-reports-that-the-resubmitted?utm_content=387419442&utm_medium=social&utm_source=linkedin&hss_channel=lcp-37897480